NY-SHISEIDO
Shiseido Company, Limited (“Shiseido”), a leading global beauty company, and Tory Burch LLC (“Tory Burch”) today announced that they have entered into a long-term partnership agreement under which Shiseido will have the exclusive worldwide license to develop, market, and distribute Tory Burch beauty brands. The agreement will be effective as of January 1, 2020. Tory Burch’s beauty license will be managed by Shiseido Group’s Americas region headquartered in New York City.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005529/en/
Tory Burch is an American lifestyle brand that embodies the personal style, global mindset and aesthetic of its Executive Chairman and Chief Creative Officer, Tory Burch, a modern and dynamic entrepreneur who launched her company in 2004. Today, the collection includes ready-to-wear, shoes, handbags, accessories, watches, home and fragrance. The first Tory Burch fragrance products were launched in 2013, and are currently available in Tory Burch boutiques and luxury retailers around the world.
Through this partnership, Shiseido will provide Tory Burch with a global platform and dedicated resources to elevate the Tory Burch beauty business, and to cultivate and capture opportunities as a multi-platform, global lifestyle beauty brand. For Shiseido, this partnership will expand its global fragrance portfolio, and create opportunities for collaboration across Shiseido Group and the company’s Centers of Excellence in Fragrance, Makeup, Skincare and Digital, as well as the company’s Technology Acceleration Hub.
Masahiko Uotani, President and CEO of Shiseido, said, “Shiseido is on an exciting journey to achieve its long-term mission of BEAUTY INNOVATIONS FOR A BETTER WORLD, and we are honored to welcome Tory and the Tory Burch brand to the Shiseido family and pursue this mission together as partners. Tory Burch is a truly luxurious lifestyle brand with a clear identity and strong commitment to its values – exactly the type of innovative partner we seek to enhance our portfolio as we continue to find new ways of cultivating consumer engagement and bringing value to our business and to society. Shiseido is dedicated to creating value for all of its partners and we are excited to share the benefits of Shiseido’s platform, R&D resources, technology portfolio and Centers of Excellence with the Tory Burch brand to help maximize its significant potential and opportunities for growth and development.”
Tory Burch, Executive Chairman and Chief Creative Officer, commented: “We are thrilled to be partnering with Shiseido, a company I have always admired for its rich history, unparalleled products and dedication to innovation. There are great synergies between our companies including a deep respect and connection to our customers, a passion to support women’s empowerment and an aligned long-term strategic vision. We could not be more excited to build a global lifestyle fragrance and beauty concept in partnership with Shiseido, a realization of a long-time dream.”
Pierre-Yves Roussel, CEO of Tory Burch, added: “We are proud of what we have accomplished with our family of fragrances to date and we are extremely honored to move the business forward with this new strategic partnership. Shiseido is an influential global leader setting the highest standard of excellence in the industry. We look forward to working with them to drive the next phase of development and expansion for Tory Burch Beauty.”
Marc Rey, CEO of Shiseido Americas and Shiseido Chief Growth Officer, said, “Tory Burch is a powerhouse fashion brand that shares many of the same values as Shiseido, and we’re thrilled to be in partnership together. There’s a tremendous opportunity to grow the Tory Burch business, and Shiseido is honored to provide Tory Burch with the resources to do so. By combining Tory’s beloved vision and the brand’s future-forward approach to digital, with Shiseido’s global platform and expertise in beauty and technology, this partnership has the ability to connect even more deeply with consumers and unleash the brand’s full potential. We are especially proud to partner with Tory, who sets an example for us all as a visionary, entrepreneur and an advocate for women’s empowerment, and we look forward to working closely with the broader team.”
About Shiseido Company, Limited
Shiseido was founded in 1872 as the first Western-style pharmacy in Japan. The business gradually evolved into a cosmetics company, offering people the most advanced technology and the finest aesthetics available in the East or the West. Now, known globally as the premier cosmetics company with roots in Japan the name Shiseido has come to represent the world’s highest standard of quality in beauty. Shiseido’s global selection of skincare, makeup and fragrance includes a high-performance category for special skincare, and a brightening line. Shiseido offers products for professional beauty salons and hairdressers, as well as body care, suncare and a skincare line for men. Fiercely contemporary and innovative with over 140 years in business, the Shiseido group brands are now sold in over 120 countries. For more information, please visit http://www.shiseidogroup.com/ .
About Tory Burch
Tory Burch is an American lifestyle brand that inspires people around the world to live in full color with character, beauty and confidence. Launched in February 2004, the collection includes multiple categories ranging from footwear and handbags, to ready-to-wear and home embodying the personal style of the company’s Executive Chairman and Chief Creative Officer, Tory Burch. There are more than 250 Tory Burch boutiques across North America, Europe, the Middle East, Latin America, Asia and Australia, and the collection is available at over 3,000 department and specialty stores worldwide and toryburch.com. The brand’s dedication to helping women fearlessly follow their dreams is reflected in the work of the Tory Burch Foundation, which advances women’s empowerment and entrepreneurship in the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005529/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines13.11.2025 07:00:00 CET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used to: Advance the ongoing Phase I clinical trial of V-212, with topline results expected in Q1 2026. Prepare for a planned Phase Ib combination trial evaluating V-212 with an approved pneumococcal conjugate vaccine (PCV). Complete OPK assay validation to support immunogenicity and functional data read-outs. Implement platform enhancements to the company’s proprietary Synthetic Virus-Like Particle (SVLP) technology. Progress next-generation serotype-independent pneumococcal vaccine programs toward preclinical development. “This financing demonstrates the continued confidence and co
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom